Safety and Efficacy of Senolytic UBX1325 in Diabetic Macular Edema

202511 citationsJournal Article

Authors

Sharon Klier · Unity Biotechnology (United States)

J. Dananberg · Unity Biotechnology (United States)

Lauren Masaki · Unity Biotechnology (United States)

Robert B. Bhisitkul · University of California, San Francisco

Arshad M. Khanani · Sierra Eye Associates

Raj K. Maturi · Indiana University School of Medicine

Hani Salehi-Had

Abstract

In this sham-controlled trial there were no TEAEs that led to discontinuation of treatment with UBX1325 compared with sham. There were trends suggestive of potential efficacy; larger trials are needed to further evaluate these findings. (Funded by UNITY Biotechnology; ClinicalTrials.gov number, NCT04857996.).

Topics & Keywords

Retinal Diseases and Treatments Cytomegalovirus and herpesvirus research Advanced Glycation End Products research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: NEJM Evidence

Volume 4, Issue 5, pp. EVIDoa2400009-EVIDoa2400009

DOI: 10.1056/evidoa2400009

Field-Weighted Citation Impact: 19.37